Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis

Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e460-e463. doi: 10.1016/j.clml.2021.01.001. Epub 2021 Jan 6.

Authors

David M Hughes¹, Shayna DeMari², Hamza Hassan³, Vaishali Sanchorawala³, J Mark Sloan³

Affiliations

¹ Department of Pharmacy, Boston Medical Center, Boston, MA; Amyloidosis Center, Boston University School of Medicine, Boston, MA. Electronic address: david.hughes@bmc.org.
² Albany College of Pharmacy and Health Sciences, Albany, NY.
³ Amyloidosis Center, Boston University School of Medicine, Boston, MA.

PMID: 33716055
DOI: 10.1016/j.clml.2021.01.001

No abstract available

Keywords: Bortezomib; Dyscrasia; Plasma cell; Refractory; XPO.

Publication types

Case Reports

MeSH terms

Humans
Hydrazines / pharmacology
Hydrazines / therapeutic use*
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Male
Middle Aged
Recurrence
Triazoles / pharmacology
Triazoles / therapeutic use*

Substances

Hydrazines
Triazoles
selinexor